FY2025 EPS Estimate for Ocular Therapeutix Raised by Analyst

Key Points

• HC Wainwright raised its FY2025 EPS estimate for Ocular Therapeutix from ($1.53) to ($1.49), maintaining a "Buy" rating with a target price of $19.00.
• Ocular Therapeutix's market capitalization is approximately $2.08 billion, with shares recently opening at $11.94 and a 12-month trading range between $5.78 and $13.85.
• Institutional investors own over 59% of Ocular Therapeutix's stock, with notable recent increases in stakes by various investment firms like Adage Capital Partners and Invesco Ltd.

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Investment analysts at HC Wainwright increased their FY2025 earnings per share (EPS) estimates for Ocular Therapeutix in a note issued to investors on Wednesday, October 8th. HC Wainwright analyst Y. Chen now expects that the biopharmaceutical company will post earnings per share of ($1.49) for the year, up from their prior estimate of ($1.53). HC Wainwright currently has a "Buy" rating and a $19.00 target price on the stock. The consensus estimate for Ocular Therapeutix's current full-year earnings is ($0.98) per share. HC Wainwright also issued estimates for Ocular Therapeutix's Q4 2025 earnings at ($0.33) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.31) EPS and FY2026 earnings at ($1.24) EPS.

A number of other equities analysts also recently issued reports on the company. Piper Sandler raised their price objective on Ocular Therapeutix from $21.00 to $31.00 and gave the stock an "overweight" rating in a research report on Friday, October 3rd. Scotiabank lowered their price objective on Ocular Therapeutix from $22.00 to $20.00 and set a "sector outperform" rating for the company in a research report on Wednesday, August 6th. JMP Securities raised their price objective on Ocular Therapeutix from $20.00 to $29.00 and gave the stock a "market outperform" rating in a research report on Wednesday, October 1st. Zacks Research upgraded Ocular Therapeutix from a "strong sell" rating to a "hold" rating in a research report on Thursday, October 2nd. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Ocular Therapeutix in a research report on Wednesday. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Ocular Therapeutix presently has a consensus rating of "Moderate Buy" and an average target price of $22.63.

Ocular Therapeutix Stock Performance

Shares of OCUL stock opened at $11.94 on Friday. The business's 50-day moving average price is $12.28 and its 200-day moving average price is $9.83. Ocular Therapeutix has a 12 month low of $5.78 and a 12 month high of $13.85. The firm has a market capitalization of $2.08 billion, a price-to-earnings ratio of -9.33 and a beta of 1.45. The company has a current ratio of 10.10, a quick ratio of 10.02 and a debt-to-equity ratio of 0.23.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.04). Ocular Therapeutix had a negative net margin of 382.51% and a negative return on equity of 71.92%. The firm had revenue of $13.46 million for the quarter, compared to analyst estimates of $13.12 million. During the same period in the previous year, the business posted ($0.26) earnings per share. The business's revenue for the quarter was down 17.7% compared to the same quarter last year.

Insider Buying and Selling at Ocular Therapeutix

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,494 shares of the business's stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $12.04, for a total value of $258,787.76. Following the transaction, the insider directly owned 3,227,244 shares of the company's stock, valued at approximately $38,856,017.76. The trade was a 0.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jeffrey S. Heier sold 10,502 shares of the business's stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $11.04, for a total value of $115,942.08. Following the completion of the transaction, the insider directly owned 249,409 shares in the company, valued at approximately $2,753,475.36. This trade represents a 4.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,674 shares of company stock valued at $590,279. 2.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Ocular Therapeutix

Several institutional investors have recently added to or reduced their stakes in OCUL. Adage Capital Partners GP L.L.C. raised its position in shares of Ocular Therapeutix by 44.4% during the first quarter. Adage Capital Partners GP L.L.C. now owns 5,200,000 shares of the biopharmaceutical company's stock worth $38,116,000 after purchasing an additional 1,600,000 shares during the period. Deltec Asset Management LLC raised its position in shares of Ocular Therapeutix by 2.9% during the second quarter. Deltec Asset Management LLC now owns 2,794,892 shares of the biopharmaceutical company's stock worth $25,937,000 after purchasing an additional 78,519 shares during the period. Invesco Ltd. raised its position in shares of Ocular Therapeutix by 91.2% during the second quarter. Invesco Ltd. now owns 1,538,846 shares of the biopharmaceutical company's stock worth $14,280,000 after purchasing an additional 734,017 shares during the period. Paradigm Biocapital Advisors LP acquired a new position in shares of Ocular Therapeutix during the first quarter worth approximately $9,632,000. Finally, Raymond James Financial Inc. raised its position in shares of Ocular Therapeutix by 142.8% during the second quarter. Raymond James Financial Inc. now owns 884,381 shares of the biopharmaceutical company's stock worth $8,207,000 after purchasing an additional 520,138 shares during the period. 59.21% of the stock is owned by institutional investors and hedge funds.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.